SavedAdd your journal

Journals / Medeniyet Medical Journal / 2018 / Cilt: 33 - Sayı: 4

Prevalence of metabolic syndrome in hypothyroid patients under Levothyroxine therapy

Mumtaz TAKIR
Muhammed KIZILGÜL
Pages
257–262
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Moreo-ver, more comprehensive studies should be performed in a larger -scale population to enlighten this association.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Since thyroid hormones have an impact on lipid and glu-cose metabolism, thyroid dysfunction is a risk factor for cardio-vascular diseases.
📊
Key Findings & Data:Studies have demonstrated that thyroid dysfunction corresponds to a higher prevalence of MS.
💡
Conclusion & Impact:Moreo-ver, more comprehensive studies should be performed in a larger -scale population to enlighten this association.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Aim: Since thyroid hormones have an impact on lipid and glu-cose metabolism, thyroid dysfunction is a risk factor for cardio-vascular diseases. Metabolic syndrome (MS) is related to higher risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Studies have demonstrated that thyroid dysfunction corresponds to a higher prevalence of MS. Additionally, some studies have showed patients with MS had a higher prevalence of hypothyroidism. We aimed to investigate whether hypothyroid patients being treated with levothyroxine still have a higher pre-valence of metabolic syndrome or not.Methods: One hundred and eighty-six hypothyroid patients (175 female, 11 male) using levothyroxine treatment were included in the study. Demographic, anthropometric and laboratory me-asures were recorded. International Diabetes Federation (IDF) criteria were used for diagnosis of MS.Results: The prevalence of MS was 52% in hypothyroid patients using levothyroxine. Mean age was 48.44±14.90 years. Mean TSH was 1.94±1.11 uIU/L and mean free T4 was 1.06±0.20 (ng/dL). Mean weekly levothyroxine dose was 537.01 mcg. We-ekly levothyroxine dose was positively correlated with weight (r2:0.188, p:0.010), BMI (r2:0.227, p:0.026) and waist circumfe-rence (r2:0.164, p:0.026). Weekly levothyroxine dose was also positively correlated with LDL-cholesterol (r2:0.167, p:0.031) and HbA1c (r2:0.180, p:0.034) levels. Weekly levothyroxine dose was not correlated with other cardiometabolic risk factors (p>0.05).Conclusions: The prevalence of metabolic syndrome is still high in hypothyroid patients under levothyroxine treatment. Moreo-ver, more comprehensive studies should be performed in a larger -scale population to enlighten this association.

🔖

Cite This Article

TAKIR, M., KIZILGÜL, M. (2018). Prevalence of metabolic syndrome in hypothyroid patients under Levothyroxine therapy. Medeniyet Medical Journal, Cilt: 33 - Sayı: 4, 257–262. https://ajindex.com/articles/283315

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Almandoz JP, Gharib H. Hypothyroidism: Etiology, Diagnosis, and Management. Med. Clin. North Am. 2012;96(2):203-221.
  2. Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V. Thyroid dysfunction and serum lipids: A community-based study. Clin. Endocrinol. (Oxf). 2005;63(6):670-675.
  3. Kizilgul M, Uzunlulu M, Karacakaya M, Semerci A, Isbilen B IF. Pentraxin 3 Levels as a Marker of Chronic Inflammation in Patients With Metabolic Syndrome. J Endocrinol Metab 2012;2(6):220-227.
  4. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: Definition, pathophysiology, and mechanisms. In: American Heart Journal. Vol 149.;2005:33-45.
  5. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome - A new worldwide definition. Lancet 2005;366(9491):1059-1062.
  6. Gundogan K, Bayram F, Gedik V, Kaya A, Karaman A, Demir O, Sabuncu T, Kocer D, Coskun R. Metabolic syndrome prevalen-ce according to ATP III and IDF criteria and related factors in Turkish adults. Arch. Med. Sci. 2013;9(2):243-253.
  7. Erdogan M, Canataroglu a, Ganidagli S, Kulaksızoglu M. Me-tabolic syndrome prevalence in subclinic and overt hypoth-yroid patients and the relation among metabolic syndrome parameters. J. Endocrinol. Invest. 2011;34(7):488-92
  8. Bamashmos MA, Atef ZA. The prevalence of metabolic syndrome in Yemeni patients with hypothyroidism. WORLD Fam. Med. 2016;14(6):29-36.
  9. Uzunlulu M, Yorulmaz E, Oguz A. Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. En-docr. J. 2007;54(1):71-76.
  10. Khatiwada S, Sah SK, KC R, Baral N, Lamsal M. Thyroid dysfunc-tion in metabolic syndrome patients and its relationship with components of metabolic syndrome. Clin. Diabetes Endocri-nol. 2016;2(1):3.
  11. Lee YK, Kim JE, Oh HJ, Park KS, Kim SK, Park SW, Kim MJ, Cho YW. Serum TSH level in healthy koreans and the association of TSH with serum lipid concentration and metabolic syndro-me. Korean J. Intern. Med. 2011;26(4):432-439.
  12. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the Int